A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2016
At a glance
- Drugs Peficitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Astellas Pharma
- 07 Jun 2017 Biomarkers information updated
- 16 Oct 2016 Results published in the Arthritis and Rheumatology.
- 25 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.